Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
The Burrill Report
»
Articles
»
INHX
|
The Burrill Report
208
Followers
2
Following
You are currently following The Burrill Report
Stop Following
You are no longer following The Burrill Report
Profile
Articles (59)
Financing Activity for Biotech Deals Heats Up
on Sep 27, 2009
•
ABT
,
AZN
,
BIIB
More on INHX by The Burrill Report
Instablogs »
StockTalks »
Comments »
Articles by Ticker
A
,
ABT
,
ACOR
,
ADM
,
AEZS
,
AFPC
,
ALDH
,
ALIOF.PK
,
ALPMF.PK
,
ALTU
,
AMGN
,
AMLN
,
ANDS
,
ANSV
,
APPA
,
ARIA
,
ARKTF.PK
,
ARYX
,
AVGN
,
AVII
,
AZN
,
BFRE.OB
,
BIIB
,
BIOVY.PK
,
BMTI
,
BMY
,
BPA
,
BVF
,
BYERF.PK
,
CADX
,
CBST
,
CCM
,
CEGE
,
CELG
,
CEPH
,
CGRB
,
CHTT
,
CLDA
,
CLDX
,
CNSO.OB
,
CPIX
,
CRA
,
CRGN
,
CRXX
,
CTIC
,
CVM
,
CYTK
,
CYTX
,
DCGN
,
DHR
,
DNA
,
DNDN
,
DYAX
,
EDEN
,
ELN
,
ELXR
,
EM
,
ENDP
,
EPIX
,
ESRX
,
EXEL
,
FACT
,
FCSC.OB
,
FRX
,
GE
,
GENZ
,
GERN
,
GETA.OB
,
GILD
,
GNMSF.PK
,
GSK
,
GTXI
,
HALO
,
HGSI
,
HLCS
,
HNAB
,
ICGN
,
IDIX
,
IMCL
,
IMGN
,
IMMU
,
INCY
,
INHX
,
ISIS
,
ISPH
,
ITMN
,
IYH
,
IYR
,
JAV
,
JNJ
,
KERX
,
LGND
,
LIFE
,
LJPC
,
LLY
,
LXRX
,
LZAGF.PK
,
MAPP
,
MATK
,
MBRX
,
MDCO
,
MDVN
,
MDZ
,
MEDX
,
MIPI
,
MITI
,
MJN
,
MNKD
,
MNOV
,
MNTA
,
MRK
,
MSFT
,
MYL
,
MYRX
,
NABI
,
NKBP
,
NKTR
,
NVO
,
NVS
,
OGXI
,
OMER
,
ONXX
,
OPXA
,
OREX
,
OSCI
,
OSIP
,
PARD
,
PEIX
,
PFE
,
PG
,
PKNGF.PK
,
PPDI
,
PRU
,
QGEN
,
RDY
,
REGN
,
RGEN
,
RHHBY.PK
,
RIGL
,
RPRX
,
RXII
,
SEM
,
SEPR
,
SGEN
,
SGMO
,
SGP
,
SHPGY
,
SLF
,
SLFPF.PK
,
SNY
,
SOMX
,
SPHDF.PK
,
STEM
,
SUPG
,
SVNT
,
SVYSY.PK
,
SYT
,
TEVA
,
TGEN
,
TKPHF.PK
,
TLCR
,
TMO
,
TPTX
,
TRBN
,
TRGT
,
TSMA
,
TSPT
,
TTHI
,
TTP
,
UGNE.OB
,
VAR
,
VION.OB
,
VRNM
,
VRTX
,
VRX
,
VVUS
,
WCRX
,
WPI
,
WYE
,
XLV
,
ZGEN
Latest Comments on The Burrill Report's Articles
Krishnendu Saha
on
Sanofi-Aventis Reaches over the Counter
: Just wondering whether Lovenox, Plavix & Ambien can ever be OTC...
more »
DanHaszard
on
Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
: Addictive Zyprexa was pushed by Lilly Drug Reps. They called it...
more »
On Point Advisor
on
Sanofi-Aventis Reaches over the Counter
: please see story in OTC Product News [www.otcproductnews.com]
more »
jay brebner
on
This Week's Biotech Deal-Making and Financing
: Aveo is definitely the company to own for the long haul as well as...
more »
Factation
on
This Week's Failed Trials, Missed Targets in Biotech
: Relating to, "A gel designed to prevent AIDS infections produced...
more »
johnnysize
on
Bristol-Myers Squibb Sees Perfect Timing to Divest Huge Mead Johnson Nutrition Stake
: Thanks Monkeys... I now own a cheap takeout stock with huge growth...
more »
Alessandro
on
BlueFire, Archer Daniels to Benefit from Federal Biorefinery Millions
: I saw a television special espousing the benefits of biochar and...
more »
Alessandro
on
BlueFire, Archer Daniels to Benefit from Federal Biorefinery Millions
: On Dec 13 07:47 PM auto44 wrote: > You are supposed to sell BS...
more »
BioGuy
on
Biotech's Latest Failed Trials, Missed Targets
: I think ZymoGenetics was smart to change it's focus to creating...
more »
Erich J Knight
on
BlueFire, Archer Daniels to Benefit from Federal Biorefinery Millions
: All political persuasions agree, building soil carbon is GOOD. To...
more »
auto44
on
BlueFire, Archer Daniels to Benefit from Federal Biorefinery Millions
: You are supposed to sell BS not buy it. On Dec 13 10:13 AM...
more »
johnnysize
on
Bristol-Myers Squibb Sees Perfect Timing to Divest Huge Mead Johnson Nutrition Stake
: oh gee...thats option expiration ...wow. maybe now proration...
more »
uncle mike
on
Life Sciences Co. Execs Enjoying Pay Hikes in the Downturn
: bios are always iffee but if you pick them right buy in and out...
more »
valuestocksonly
on
BlueFire, Archer Daniels to Benefit from Federal Biorefinery Millions
: BFRE is going to play a large role in this nations energy...
more »
Walt17
on
Eli Lilly Plans Innovation Strategy to Counter Generics Threat
: Lilly acknowledges the generic competition. Why does this surprise...
more »
Latest Comments on The Burrill Report's Articles
Latest Comments on The Burrill Report's Articles